Dr. Axel Müller – Profile

longtime experience in Executive Management and Consulting, e.g. Executive Board Member and Supervisory Board Member of stock noticed companies (segments: MDAX, Prime Standard), Advisory Board Member of medium- sized companies as well as Senior Advisor of international consultancy firms

Successful management responsibilities in:
- Corporate management:
  as of 2020 Chairman of the Advisory Board of MIP Pharma Group
  – a medium-sized pharmaceutical Group with own production, a focus on Generics/Antibiotics and >40 Mio. € sales
  
  as of 2018 Supervisory Board Member at Mutares (Mutares SE & Co. KGaA as well as Mutares Management SE)
  – stock noticed Private Equity Company (SDAX) with approx. 3 Mrd. € sales and a focus on restructuring companies in numerous industries
  
  2010 – 2013 Executive Board member of STADA Arzneimittel AG
  - globally active pharmaceutical company with > 2 bill. € sales and > 8,000 employees wordwide at that time
- Division responsibility as Executive Board member for production, product development incl. regulatory affairs, sourcing and supply chain, licening, QA/QC, portfolio management with >5,000 employees and >20 facilities worldwide.
- Corporate development:
  Head of corporate development responsible for initiating and controlling M&A processes including acquisitions and divestment processes.
- Marketing and sales:
  Director of generics, OTC and brand businesses in different European markets.
- Communications:
  Long-term responsibility for global enterprise communications and investor relations.
Many years of strategic consulting at the executive level.
Capital market expertise and confident with investors and bankers.
Distinctive practical experience in change management, drafting and implementing corporate governance changes and cost optimization programmes.